Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Optimizing prostate cancer suicide gene therapy using herpes simplex virus thymidine kinase active site variants.

Human gene therapy - 1 May 2002

Pantuck Allan J, Matherly Jamie, Zisman Amnon, Nguyen David, Berger Frank, Gambhir Sanjiv S, Black Margaret E, Belldegrun Arie, Wu Lily

Abstract excerpt

The herpes simplex virus (HSV) thymidine kinase gene (tk) forms the basis of a widely used strategy for suicide gene therapy. A library of HSV thymidine kinase enzyme (TK) active site mutants having different affinities for guanosine analog prodrugs was developed. We sought to determine the optimal combination of tk variant and prodrug specifically for prostate cancer gene therapy, using in vitro and in vivo...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Acyclovir
Share to Ganciclovir

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Guanosine

Share to Prodrugs

Share to Simplexvirus

Share to Tetrazolium Salts

Share to Thymidine Kinase

Share to Tomography, Emission-Computed

Source

Identifiers

PMID: 11975845
DOI: 10.1089/10430340252898966

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Optimizing prostate cancer suicide gene therapy using herpes simplex virus thymidine kinase active site variants.PMID 11975845Read ↗

Enhancement of tumor ablation by a selected HSV-1 thymidine kinase mutant.Semantic proximity Read ↗

Characterization of herpes simplex virus type 1 thymidine kinase mutants engineered for improved ganciclovir or acyclovir activity.Semantic proximity Read ↗

Suicide gene therapy mediated by the Herpes Simplex virus thymidine kinase gene/Ganciclovir system: fifteen years of application.Semantic proximity Read ↗

Enhanced antitumor efficacy of a herpes simplex virus mutant isolated by genetic selection in cancer cells.Semantic proximity Read ↗

Oncolytic viral gene therapy for prostate cancer using two attenuated, replication-competent, genetically engineered herpes simplex viruses.Semantic proximity Read ↗

Mutation of herpesvirus thymidine kinase to generate ganciclovir-specific kinases for use in cancer gene therapies.Semantic proximity Read ↗

Transduction of human pancreatic tumor cells with vesicular stomatitis virus G-pseudotyped retroviral vectors containing a herpes simplex virus thymidine kinase mutant gene enhances bystander effects and sensitivity to ganciclovir.Semantic proximity Read ↗

Creation of drug-specific herpes simplex virus type 1 thymidine kinase mutants for gene therapy.Semantic proximity Read ↗

A polymer library approach to suicide gene therapy for cancerSemantic proximity Read ↗

T cell transduction and suicide with an enhanced mutant thymidine kinase.Semantic proximity Read ↗

Multimodality therapy with a replication-conditional herpes simplex virus 1 mutant that expresses yeast cytosine deaminase for intratumoral conversion of 5-fluorocytosine to 5-fluorouracil.Semantic proximity Read ↗

A new acycloguanosine-specific supermutant of herpes simplex virus type 1 thymidine kinase suitable for PET imaging and suicide gene therapy for potential use in patients treated with pyrimidine-based cytotoxic drugs.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.